PMN Stock Price, Chart, Stats & News
ProMIS Neurosciences, Inc. (PMN) does not currently pay a dividend.
PMN chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -432.56% |
ROE | 12809.37% |
D/E | – |
Interest coverage ratio | – |
PMN valuation
P/E | – |
P/S | – |
P/B | -0.02x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | 0.00x |
EV multiple | -0.15x |
About
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease.
Similar securities
Based on sector and market capitalization
